EMEA-002705-PIP01-19

Table of contents

Key facts

Active substance
(2S,4S)-2-(4-Carboxyphenyl)-4-ethoxy-1-[(5-methoxy-7-methyl-1H-indol-4-yl)methyl]piperidin-1-ium chloride―water (1/1) (LNP023)
Therapeutic area
Other
Decision number
P/0417/2020
PIP number
EMEA-002705-PIP01-19
Pharmaceutical form(s)
  • Capsule, hard
  • Age-appropriate oral solid dosage form
Condition(s) / indication(s)
Treatment of C3 glomerulopathy
Route(s) of administration
Oral use
Contact for public enquiries
Novartis Europharm Limited

E-mail: paediatric.enquiries@novartis.com
Tel. +41 6132 41111

Decision type
P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)

Decision

How useful was this page?

Add your rating